Exploring neoadjuvant therapy for lung cancer
Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
This study is testing how well different treatments before surgery, like chemotherapy and immunotherapy, can help people with lung cancer and what factors might affect their success.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06216782 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of various neoadjuvant therapies, including chemotherapy, immunotherapy, and targeted therapy, in patients with lung cancer. It focuses on understanding how different patient characteristics influence treatment outcomes and the long-term survival rates associated with these therapies. By analyzing real-world clinical data, the study seeks to identify the strengths and weaknesses of different neoadjuvant regimens in improving surgical resection rates and overall therapeutic effects.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of non-small cell lung cancer or small cell lung cancer who have received neoadjuvant therapy.
Not a fit: Patients currently enrolled in other clinical trials or those who refuse follow-up may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies that enhance survival rates for lung cancer patients.
How similar studies have performed: Previous studies have shown promising results with neoadjuvant therapies in lung cancer, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age greater than or equal to 18 years; 2. Pathohistologically confirmed diagnosis of non-small cell lung cancer or small cell lung cancer; 3. Received neoadjuvant therapy after diagnosis; 4. Written informed consent. Exclusion Criteria: 1. Patients enrolled in other clinical trials; 2. Patients refused enrollment in this study; 3. Patients refused follow-up.
Where this trial is running
Shanghai, Shanghai Municipality
- Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Principal investigator: Peng Zhang, Ph.D. — Shanghai Pulmonary Hospital, Shanghai, China
- Study coordinator: Peng Zhang, Ph.D.
- Email: zhangpeng1121@tongji.edu.cn
- Phone: 021-55672180
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.